Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

July 23, 2025
Otsuka Pharmaceutical

Free Outdoor Live Music Event “EXCITING SUMMER in WAJIKI 2025” Live Stage Will Run on Solar Power Promoting More Sustainable Event Experience
July 19, 2025
Otsuka Pharmaceutical

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
July 15, 2025
Otsuka Pharmaceutical

Otsuka Acquires Worldwide Rights to Cantargia’s CAN10 for Development and Commercialization as a Potential Treatment for Autoimmune Diseases
July 11, 2025
Otsuka Holdings

Otsuka Holdings Selected as a Constituent of ESG Investment Indexes: FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
July 10, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical and Taiho Oncology Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
July 9, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Launches Sales of POCARI SWEAT in India Expanding the Nutraceutical Business Globally
July 8, 2025
Taiho Pharmaceutical

Phase III Clinical Study with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan Did Not Meet Its Primary Endpoint
July 3, 2025
Otsuka Pharmaceutical

eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System
July 1, 2025
Otsuka Pharmaceutical

Otsuka Launches Comprehensive Support Program for Families of People with Severe Social Withdrawal (Hikikomori) in Collaboration with Hokkaido University
June 30, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Launches Portal for Corporate Health Services Empowering Employee Health Through Several Service Options
June 26, 2025
Otsuka Foods

Otsuka Foods to Launch “Bon Curry GOLD Uma-Kara Butter Chicken Style: Summer Extra Hot” A Special Limited-Edition Curry Offering “Spiciness with Deep Umami” In Stores across Japan on July 7, 2025
June 25, 2025
Otsuka Pharmaceutical

POCARI SWEAT ICE SLURRY Adopted as a New Heat Illness Prevention at Expo 2025 Osaka, Kansai, Japan, Supporting the Safe and Secure Operation of the Expo
June 23, 2025
Otsuka Pharmaceutical

Otsuka Obtains Exclusive License from Harbour BioMed for HBM7020: A Novel BCMAxCD3 Bispecific T-Cell Engager
June 17, 2025
Otsuka Pharmaceutical

New smartphone app, Rejoyn®, launched in Great Britain as a treatment for those living with depressive disorder
June 6, 2025
Otsuka Pharmaceutical

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
June 4, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical and SyntheticGestalt Implements Technology Validation Towards Generative AI-Driven Expansion of Cysteinomix Drug Discovery Platform
June 2, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical Out-Licenses LSD1 Inhibitor, TAS1440 to Benz Sciences
May 26, 2025
Otsuka Pharmaceutical

Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
May 23, 2025
Taiho Pharmaceutical

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
May 23, 2025
Taiho Pharmaceutical

Results of Clinical Study of the Combination Regimen of Decitabine and Cedazuridine Plus Venetoclax for Acute Myeloid Leukemia Announced at the American Society of Clinical Oncology Annual Meeting
May 19, 2025
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory launches "HINEX Jelly Aqua," a concentrated liquid diet product to assist hydration
May 9, 2025
Otsuka Pharmaceutical

Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy Supplements Facilitating the Research and Development of Gummy Products
May 8, 2025
Otsuka Pharmaceutical

Otsuka Signs Joint Research Agreement with Keio University Industry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan
May 2, 2025
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory America, Inc. Acquires 60% Interest in Otsuka ICU Medical LLC and Subsidiarizes
April 15, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in Vietnam Supporting Health and Meeting Growing Demand
April 1, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human Potential Provide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan
March 31, 2025
Otsuka Pharmaceutical Factory

J.O. Pharma installs electricity from renewable sources to contribute to a decarbonized society
March 31, 2025
Otsuka Pharmaceutical

Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
March 28, 2025
Otsuka Holdings

Otsuka Holdings appoints Board Members and Auditors and Supervisory Board Members
March 24, 2025
Otsuka Pharmaceutical Factory

Announcement of Price Revisions for Oronine H Ointment

Otsuka Group News

First 30 results